



**ODISHA**  
NEW OPPORTUNITIES



# Odisha Pharmaceutical & Medical Devices Policy 2025

Industries Department, Government of Odisha

Making Odisha the New Centre for Pharmaceutical and Medical Devices Manufacturing



**INVEST IN ODISHA, INVEST IN FUTURE**



**ODISHA**  
NEW OPPORTUNITIES

# Odisha Pharmaceutical & Medical Devices Policy 2025

Government of Odisha  
Industries Department

---

Resolution No.: 12400/I., Date: 12/12/2025



Odisha stands at the threshold of a new era of growth. With rich natural resources, skilled people, and fast-expanding infrastructure, the State is rapidly emerging as a centre of enterprise and innovation in Eastern India. Guided by Samrudh Odisha 2036 and Viksit Bharat 2047, our focus is to build an economy that creates opportunities for every citizen and strengthens Odisha's role in India's growth story.

The pharmaceutical and medical devices sector is a key pillar of this progress. Under the visionary leadership of Hon'ble Prime Minister Shri Narendra Modi Ji, India aims to become a global hub for affordable, innovative healthcare. Odisha is ready to play a vital role in this mission by positioning itself as the Eastern Gateway of India's Health Economy.

The Odisha Pharmaceutical and Medical Devices Policy 2025 is an important step in this direction. It reflects our commitment to boost domestic manufacturing, foster research and innovation, and enhance industry competitiveness. The policy introduces a modern and supportive framework - including dedicated Pharma and MedTech parks, advanced infrastructure, research clusters, skill development initiatives, technology adoption, progressive incentives, and faster clearances to ensure an investor-friendly experience.

Our vision is to make Odisha a major hub for pharmaceuticals, bulk drugs, medical devices, and biotechnology - driving innovation, quality, and sustainability. This policy lays a strong foundation for a robust healthcare manufacturing ecosystem.

I warmly invite investors, innovators, and entrepreneurs to partner with us. Together, let us build a vibrant life-science ecosystem that accelerates Odisha's industrial growth and contributes to a healthier, self-reliant, and prosperous India.

**Shri Mohan Charan Majhi**

Hon'ble Chief Minister, Odisha



It gives me immense pleasure to know about the publication of the Odisha Pharmaceutical and Medical Devices Policy 2025, a visionary step towards transforming our State into a robust hub for pharmaceutical innovation, healthcare manufacturing and medical technology.

This policy will prepare a planned strategic and cluster-based roadmap to establish Odisha as a gateway to health manufacturing and life sciences in India. The policy envisions the Odisha Pharma Park and Odisha Medtech Park to provide the necessary industrial infrastructure.

This policy reflects the commitment of the Government of Odisha to strengthen our healthcare ecosystem through strategic infrastructure development, investment promotion, research encouragement, and industry-academia collaboration. By creating an enabling environment for world-class pharmaceutical units, medical device manufacturing, and biotechnology ventures, the policy opens up new horizons for sustainable growth, employment generation and improved healthcare access for our people.

Best wishes for the Odisha Pharmaceutical and Medical Devices Policy 2025.

**Dr Mukesh Mahaling**  
Hon'ble Minister, Health and Family Welfare  
Government of Odisha



Odisha today stands at a defining moment in its industrial journey. The state is fast emerging as one of India's most stable, progressive, and investment-friendly destinations, supported by world-class infrastructure, a forward-looking governance, and a strong culture of partnership with industry.

The Odisha Pharmaceutical and Medical Devices Policy 2025 represents a strategic and timely response to global shifts in the life-sciences and healthcare manufacturing ecosystem. As the world looks to India for reliable, affordable, and high-quality pharmaceutical and MedTech solutions, Odisha is ready to play a central role in advancing this national mission.

This Policy introduces a future-ready framework to position Odisha as the Eastern Gateway of India's Health Economy. It brings together several key pillars:

- creation of globally benchmarked industrial parks for pharmaceuticals and medical devices;
- robust support for bulk drug, formulations, biosimilars, and MedTech manufacturing;
- a strong emphasis on research, testing, innovation, and skill development; and
- a progressive incentive architecture designed to attract high-value, technology-driven investments.


The facilitative role of IPICOL, IDCO, and the newly constituted Odisha Pharmaceutical Development Cell (OPDC) ensures that investors experience seamless clearances, real-time support, and a competitive operating environment.

The Industries Department is fully committed to steering this transformation by fostering partnerships with global and domestic companies, MSMEs, research institutions, and entrepreneurs. We envision Odisha emerging not only as a manufacturing powerhouse but also as a centre for innovation, design, and regulatory excellence in the life-sciences domain. I invite industries, investors, and innovators to join hands with us in building a world-class pharmaceutical and medical devices ecosystem in Odisha, an ecosystem that will empower India's healthcare ambitions, create large-scale employment, catalyse exports, and drive long-term industrial prosperity.

**Shri Sampad Chandra Swain**

Hon'ble Minister, Industries  
Government of Odisha

## Industry Ready Infrastructure



## Contents

1. Background	08
1.1. Pharmaceuticals	08
1.2. Medical Devices	08
2. Introduction	09
2.1. Vision	09
2.2. Mission	09
2.3. Objectives	09
3. Policy Framework	11
3.1. Infrastructure Development	11
3.2. Investment Promotion and Facilitation	12
3.3. Institutional Framework	12
3.4. Skill Development	13
4. Incentive Framework	15
4.1. Eligibility	15
4.2. General Provisions	16
4.3. Incentives	17
5. Revival of Sick Industrial Units	23
6. Miscellaneous	24
Annexure I - Definitions and Interpretations and Abbreviations	25
Annexure II - Recognized Industrial Activities under this Policy	30

## **1. Background**

Odisha, strategically located on India's eastern seaboard, is undergoing a phase of transformative industrial growth. With a robust GSDP growth of 10% in FY 2024-25, a balanced economic structure, and accelerated infrastructure development across logistics, power, and digital governance, the state is now poised to emerge as a major player in India's pharmaceuticals and medical devices sectors.

The post-COVID global realignment in healthcare and manufacturing has opened a new window for India to position itself as the Pharmacy of the World, a MedTech innovation hub, and a leading centre for clinical care. While western and southern states have capitalized early on these shifts, eastern India continues to be under-represented in the life sciences value chain. Odisha aims to bridge this regional imbalance by becoming the Eastern Gateway of India's Health Economy, through an integrated & forward-looking policy that brings together two high-potential sectors viz. pharmaceuticals & medical devices within a unified strategic framework.

### **1.1. Pharmaceuticals**

India's pharmaceutical industry, valued at USD 58 billion in 2025, is projected to reach USD 120–130 billion by 2030. Odisha, with its low cost of doing business and clean coastal environment, is ideally placed to emerge as India's next API and formulation hub. The proposed development of the Odisha Pharma Park, Odisha MedTech Park, a Mega Industrial Cluster with plug-and-play infrastructure, ZLD systems, and ready utilities, will anchor this transformation.

### **1.2. Medical Devices**

India imports nearly 80% of its medical devices, creating a pressing need for domestic capacity building. This segment ranging from diagnostic equipment and surgical consumables to implantable devices, and wearable Healthtech is witnessing double-digit growth. By promoting MedTech manufacturing clusters Odisha aims to reduce import dependency and promote Make in Odisha for MedTech.

## **2. Introduction**

The Government of Odisha, through the Odisha Pharmaceutical and Medical Devices Policy – 2025, envisions creating a competitive, innovation-driven, and socially responsive ecosystem for the life sciences and healthcare sector. This policy seeks to position Odisha as the Eastern Gateway of India's Health Economy. Anchored in the state's Industrial Policy Resolution (IPR) – 2022 which identifies Pharmaceuticals, Bulk Drugs, and Medical Devices as a Thrust Sector, this policy promotes infrastructure readiness, research excellence, public-private partnerships, and a facilitative regulatory environment to enable inclusive and sustainable industrial development.

The policy aims to attract investment and catalyze:

- i Local entrepreneurship and MSME development
- ii Job creation across skilled and semi-skilled segments
- iii Export-oriented manufacturing in bulk drugs, APIs, and MedTech

This comprehensive initiative supports the Odisha Vision 2036 aligning with national vision of Viksit Bharat 2047 and contributes to India's aspiration to become the Global Health Capital.

### **2.1. Vision**


To position Odisha as a leading hub for pharmaceuticals and medical devices driven by innovation, sustainability, and equitable access by 2036.

### **2.2. Mission**

To create an integrated life science and healthcare ecosystem in Odisha by developing world-class infrastructure, facilitating investment through progressive policies, promoting local entrepreneurship, and enhancing institutional capacity for R&D and innovation.

### **2.3. Objectives**

1. Attract ₹25,000 crore in investments in pharmaceutical and medical devices by 2030.
2. Generate over 1 lakh jobs, directly and indirectly, through value chain expansion and workforce skilling by 2030.

- 
3. Establish Odisha Pharma Park and Odisha MedTech Park as Eastern India's anchor for health sciences manufacturing and exports.
  4. Provide support and regulatory facilitation to Pharma and MedTech manufacturers.
  5. Strengthen research and development through focused funding, creation of world-class infrastructure, and robust industry-academia collaboration.
  6. Foster sustainable growth by encouraging adoption of green technologies and enhanced regulatory compliance.
  7. Support the Samrudh Odisha 2036 vision by driving export-led, inclusive growth in the life sciences sector.

### **3. Policy Framework**

The policy is built on five strategic enablers of Infrastructure Development, Investment Promotion and Facilitation, Institutional Framework, Skill Development, and a comprehensive Incentive Framework that together creates an enabling ecosystem for investment, innovation, and equitable growth in pharmaceuticals and medical devices sectors.

#### **3.1. Infrastructure Development**

The Odisha Pharmaceuticals and Medical Devices Policy 2025 prioritize the development globally benchmarked infrastructure to facilitate pharmaceutical manufacturing, research, and exports.

- i IDCO shall maintain a dedicated Land Bank comprising pre-identified parcel for pharmaceutical projects, ensuring concessional pricing and fast-track allotment to eligible units.
- ii Odisha Pharma Park, the state's proposed flagship mega pharma cluster, shall be developed over a minimum land area of 200 acres & shall offer:
  - a) Plug-and-play, GMP-compliant facilities for MSMEs and large enterprises.
  - b) Common infrastructure, Effluent Treatment Plants (ETPs), Zero Liquid Discharge (ZLD) systems, skill development centres & real-time monitoring of power, water, and regulatory compliance.
- iii Odisha MedTech Park, a dedicated industrial zone for medical equipment and consumables, shall be set up over a minimum land area of 200 acres & shall offer:
  - a) Pre-approved layouts with cleanroom infrastructure, assembly lines, and sterilization units
  - b) Common calibration and testing labs for regulatory certification
  - c) Focus on high-potential segments such as imaging equipment, diagnostic kits, wearables, and implants

The policy also supports the development of more private parks and clusters. The developers will be eligible for capital grant provided they meet compliance standards.

### **3.2. Investment Promotion and Facilitation**

To showcase Odisha as a preferred destination for global and domestic investors in pharmaceuticals and medical devices sector, the Government of Odisha shall:

- i     Conduct targeted national and international roadshows focused on Pharma and MedTech sectors.
- ii    Organize the annual Odisha Pharmaceutical Leadership Conclave under the aegis of "Utkarsh Odisha – Make in Odisha" initiative, as a global platform for investors, R&D leaders, and policymakers.
- iii   Develop and brand Odisha Pharma Park, Odisha MedTech Park and other industrial zones as investment-ready clusters, integrated with ports, CETPs/ZLD, and logistics networks.
- iv    Launch focused FDI campaigns targeting anchor investors in APIs, biosimilars, bulk drugs, diagnostics, and clinical trials.  
To enable faster clearances, simplified compliance, and post-approval handholding:
- v    The GO SWIFT portal shall function as the central platform for unified project approvals, land allotment, regulatory clearances, and real-time tracking of incentives.
- vi   The portal will be fully integrated with Online National Drugs licensing system (ONDLS) / State's Online Drugs License Management System (ODLMS) to ensure expedited, transparent, and pharma-specific licensing and regulatory approvals.

### **3.3. Institutional Framework**

To ensure coordinated governance, faster decision-making, and sector-specific facilitation:

- i     The Odisha Pharmaceutical Development Cell (OPDC) shall be developed and operationalized. It shall serve as advisory and facilitation body to support implementation, enable fast-track approvals, and ensure inter-agency coordination.
- ii    A Designated Coordinator from the State Drugs Control Administration with relevant technical expertise shall oversee day-to-day operations of OPDC, ensuring responsive investor engagement and real-time coordination with regulatory and other authorities.

Further, to ensure smooth implementation and effective investor support under this policy, the following facilitation and execution structure is institutionalized:

- iii Industrial Promotion and Investment Corporation of Odisha (IPICOL) shall act as the nodal agency for investment facilitation and approval. IPICOL shall receive all applications through the GO SWIFT portal.
- iv It shall coordinate investment appraisal, land allotment through IDCO, and the processing of incentives. It shall route eligible proposals to the DLSWCA, SLSWCA or HLCA, depending on the size of the investment, for final approval. The Drugs Controller, Odisha under Health & Family Welfare Department shall serve as the Nodal Officer and Technical Certifier for the policy. The Drugs Controller shall conduct technical scrutiny of all applications. They shall certify eligibility for policy incentives, including GMP compliance and regulatory readiness.

### **3.4. Skill Development**

As one of the core strategic enablers under this policy, the Government of Odisha aims to create a future-ready, industry-aligned talent pipeline that supports the state's vision of becoming a hub for Pharmaceuticals and MedTech manufacturing sectors.

- i Sector-Focused Skilling Interventions: Dedicated training programs will be introduced across the following focus areas:
  - a) Pharmaceuticals: formulation technicians, GMP-compliant operators, quality control and R&D professionals.
  - b) Medical Devices: cleanroom assemblers, biomedical equipment technicians, validation experts.
- ii Institutional Convergence and Academic Partnerships: The skilling ecosystem will be anchored by OSDA in partnership with:
  - a) Pharmacy and biomedical colleges for curriculum redesign, internships and research collaboration.
  - b) National-level Sector Skill Councils like LSSSDC (Life Sciences) and HSSC(Healthcare) under NSDC for certification.

- iii Incentivized Training and Employment
  - a) Incentives will be extended to employers hiring Odisha-domiciled skilled workers, especially in R&D, QA/QC, and diagnostics.
  - b) Special training modules will target youth in across districts, aligning with Odisha's inclusive growth vision.
- iv Skill Infrastructure within Industrial Ecosystems
  - a) Common Training Centres (CTCs) will be developed within the Odisha Pharma Park, MedTech Park and other clusters to provide hands-on industrial training.
  - b) Focus will also be placed on digital skilling through e-learning modules on regulatory compliance, GMP protocols, and medical device handling.

## **4. Incentive Framework**

The Incentive Framework under the Odisha Pharmaceutical and Medical Devices Policy-2025 is designed to catalyze high-value investments and drive export-led manufacturing growth in the state. Building upon the provisions of the Industrial Policy Resolution (IPR)-2022, this framework provides targeted financial and non-financial support to projects across the Pharmaceutical and Medical Devices Sectors. The incentives will be administered through detailed Operational Guidelines, notified separately by the Department of Industries, Government of Odisha.

This chapter outlines the eligibility, provisions, and structured incentives for projects across pharmaceuticals and medical devices.

### **4.1. Eligibility**

- a. All units in the pharmaceutical, Bulk Drugs (API), biotechnology-based pharmaceutical and medical device manufacturing units eligible for incentives under Odisha Industrial Policy Resolution 2022 and its subsequent amendments shall be eligible for incentives under this policy.
- b. All Expansion, Modernization, Diversification & Upgradation (E/M/D/U) units shall be treated at par with new industrial units and are eligible for incentives under this policy.
- c. To qualify for incentives under Expansion, Modernization, Diversification or Upgradation, the unit must make a minimum 50% additional investment in the undepreciated book value of Plant & Machinery as well as the following.
  - i Expansion: At least 50% increase in production capacity
  - ii Diversification: Addition of new product lines
  - iii Modernization: At least 30% improvement in energy efficiency, pollution reduction, or compliance with global certifications.
  - iv Upgradation: Improvement in quality standards and regulatory certifications as per both national and international standards like US-FDA, WHO-GMP and Revised Schedule-M of the Drugs and Cosmetics Act, 1940 C Rules, 1945.
- d. For the purpose of this policy, eligible Fixed Capital Investment (FCI) shall be limited to Plant and Machinery directly related to core manufacturing, research, testing, or regulatory compliance functions. The detailed list of eligible and non-eligible items shall be specified in the operational guidelines to be issued later.

- e. The eligible fixed capital investment must be completed within three years for MSMEs and within five years for Large, Mega, and Anchor Units from the date of first fixed capital investment.
- f. The date of commencement of commercial production should not be later than 3 years from the date of first fixed capital investment for MSMEs and 5 years from the date of first fixed capital investment for large, mega and anchor units.
- g. If the industrial unit has availed similar incentives under any other scheme of the state government or the Government of India (GoI) or Government Agencies or any Financial Institutions, it shall be eligible for the differential amount of benefit only.
- h. Undertakings carrying on activities recognized as pharmaceutical units and medical device units for the purpose of this policy are in Annexure 2.
- i. This policy shall not be applicable to the following categories:
  - i Ayurvedic, Homeopathic, Siddha, Unani & other AYUSH-based manufacturing units, which fall outside the scope of this policy.
  - ii Trading, repackaging, labelling, or distribution activities, which do not involve manufacturing, R&D, or direct industrial production, are also excluded from the purview of this policy.

#### **4.2. General Provisions**

- a. Implementation of various provisions covering the incentives, concessions, etc., will be subject to the issue of detailed guidelines/statutory notifications.
- b. An industrial unit, which considers itself eligible for any incentives, shall have to apply in accordance with this policy and the applicable Operational Guidelines (OGs), and the same shall be considered and disposed of on merit by the competent authority as may be prescribed.
- c. A unit shall only be eligible to apply for incentives within the time limit as prescribed in the operational guidelines of this policy for the different category of incentives.

- d. The date of first fixed capital investment and the date of commencement of commercial operations for availing of incentives or for any other purpose, as may be required, shall be determined by the General Manager GM, DIC for MSMEs or the Director of Industries (DI) for large industrial units based on the totality of documentary evidence.
- e. Condonation of delay for time overrun in implementation of projects, applying for incentives, or other purposes beyond the control of the industrial units may be considered by the Empowered Committee (EC) on a case-to-case basis.  
The EC may be constituted under the chairpersonship of Secretary to Government, Industries Department for Large Industries, and Secretary to Government, MSME Department for MSMEs.
- f. If an enterprise categorized as Micro, Small or Medium Enterprise (MSME) under the MSMED Act, 2006, graduates to a higher category, it shall continue to avail all non-financial benefits of its original category prescribed under IPR 2022 for a period of three years from the date of such graduation to higher category.

#### **4.3. Incentives**

The eligible units will be considered for the incentives and provisions as detailed below:

#	Incentive Particulars	Description
1	<b>Land Incentives</b>	<ul style="list-style-type: none"> <li>▪ Units employing 200 or more Skilled &amp; High Skilled Odisha-domiciled persons shall be eligible for a 50% subsidy on the concessional cost of land allotted by IDCO, excluding areas under Bhubaneswar Development Authority (BDA) and Cuttack Development Authority (CDA). The 50% subsidy on land cost shall be reimbursed after commercial production of the unit.</li> <li>▪ All other land-related benefits such as conversion fee exemption, registration fee waivers, and stamp duty exemptions shall be governed and interpreted in accordance with the provisions of IPR-2022 &amp; its subsequent amendments along with the operational guidelines.</li> </ul>

#	Incentive Particulars	Description
2	<b>Capital Investment Subsidy</b>	<ul style="list-style-type: none"> <li>▪ A Capital Investment Subsidy of 30% is applicable on investment made on eligible Plant and Machinery, by new units or units undertaking Expansion, Modernization, Diversification or Upgradation (E/M/D/U).</li> <li>▪ The subsidy will be disbursed annually on a financial year basis, and the unit can claim 6% of the overall eligible investment made till the end of the financial year on an annual basis up to 5 years from the date of commencement of commercial production.</li> </ul>
3	<b>Power Infrastructure Incentives</b>	<ul style="list-style-type: none"> <li>▪ Power Infrastructure Subsidy of 25%, limited to 1 crore per unit, shall be provided for the creation of dedicated power infrastructure essential for operational readiness. This shall include power substations, transformers, and high-tension (HT) transmission lines, installed within the unit premises or the immediate industrial zone.</li> <li>▪ All other Power and Electricity related benefits including Power Tariff Reimbursement and Electricity Duty exemption shall be governed and interpreted in accordance with the provisions of IPR-2022 &amp; its subsequent amendments along with the operational guidelines.</li> </ul>

#	Incentive Particulars	Description
4	<b>State Goods and Services Tax (SGST) Reimbursement</b>	<ul style="list-style-type: none"> <li data-bbox="653 413 1473 898">▪ All eligible pharmaceutical, bulk drugs (API), biotechnology based pharmaceutical and medical device manufacturing units shall be entitled to SGST reimbursement of 100% of net SGST paid, overall limited to 200% of the cost of plant and machinery, provided that the SGST reimbursement shall be applicable only to the net tax paid towards the state component of GST, after the full adjustment of input tax credit against output tax liability.</li> <li data-bbox="653 920 1473 1454">▪ New industrial units in the notified areas in the Biju Economic Corridor shall be eligible for reimbursement of 100% of net SGST paid, overall limited to 300% of the cost of plant and machinery, provided that the SGST reimbursement shall be eligible for reimbursement of 100% of net SGST paid, overall limited to 300% of the cost of plant and machinery, provided that the SGST reimbursement shall be applicable only to the net tax paid towards the state component of GST, after full adjustment of input tax credit against output tax liability.</li> <li data-bbox="653 1476 1473 1721">▪ The overall limit of 200% / 300% of the cost of plant and machinery is applicable to the investments made up to the first 3 years for MSMEs and first 5 years for large units from the date of first fixed capital investment made by the industrial unit.</li> <li data-bbox="653 1743 1473 1966">▪ Eligible investment in Plant &amp; Machinery of pharmaceutical, bulk drugs (API), biotechnology-based pharmaceutical and medical device manufacturing units shall be defined in Operational Guidelines.</li> </ul>

#	Incentive Particulars	Description
5	<b>Enhanced Employment Linked Incentives (ELI)</b>	<ul style="list-style-type: none"> <li>₹12,500 per month for each high-skilled male professional, scientist, or R&amp;D personnel domiciled in Odisha.</li> <li>15,000 per month for each high-skilled female or transgender professional, scientist, or R&amp;D personnel domiciled in Odisha.</li> <li>It will be available for a period of five years (60 months) from the date of commencement of commercial production subject to the condition that such payment by the unit to its workers shall be Aadhar-linked and online.</li> </ul>
6	<b>Employment Subsidy</b>	<ul style="list-style-type: none"> <li>Benefit as per the extant Industrial Policy Resolution (IPR) 2022</li> </ul>
7	<b>Environment-friendly infrastructure incentives</b>	<ul style="list-style-type: none"> <li>Benefit as per the extant Industrial Policy Resolution (IPR) 2022</li> </ul>
8	<b>Incentives for Innovations, Research &amp; Development</b>	<ul style="list-style-type: none"> <li>The State Government shall provide R&amp;D investment assistance at 50% of the eligible project cost. The maximum eligible assistance shall be up to ₹10 crore for MSMEs, up to ₹25 crore for Large Units, up to ₹50 crore for Mega Units, up to ₹100 crore for Anchor Units.</li> <li>Under industry-academia collaborative R&amp;D support, 50% incentive up to 10 crores, will be provided to pharmacy colleges and universities that establish R&amp;D centres in collaboration with industries, fostering innovation and enhancing research capabilities in the pharmaceutical and medical device sectors.</li> </ul>

#	Incentive Particulars	Description
		<ul style="list-style-type: none"> <li>Patent Support- Eligible units shall be provided financial assistance up-to ₹25 lakh per domestic patent filed and granted, up-to ₹50 lakh per international patent filed and granted.</li> </ul>
9	<b>Incentives for Private Industrial Parks</b>	<ul style="list-style-type: none"> <li>The Policy provides support for the development of common infrastructure within Pharma and MedTech Parks promoted by State Agencies or the Private Sector, with a minimum land area of 100 acres. Such support shall be provided in the form of a capital grant (excluding land), limited to 50% of the cost of such infrastructure including green measures, subject to a maximum of ₹100 crore per park, limited to first 5 parks promoted by State Agencies/Private Sector.</li> <li>The above capital grant shall also be applicable to Pharma Parks and MedTech Parks that have commenced fixed capital investment before the effective date of this policy, provided that all common infrastructures is completed within the policy period and no such incentive has been availed for the same in the past. The capital grant shall be extended only for investment made after the effective date of this policy, and the nature of common infrastructure eligible shall be defined under the operational guidelines issued for this grant.</li> </ul>

## **5. Revival of Sick Units**

- a. This policy shall also be applicable for the revival of sick industrial units. A unit shall be considered sick if it is classified as such by a recognized financial institution or the Department of MSME / Industries, Government of Odisha.
- b. The Government shall extend need-based incentives as applicable under this policy to sick units under revival. The industries under this category shall be treated at par with the new industrial units for determination of the applicable incentives.

## **6. Miscellaneous**

- a. This policy outlines the full range of financial and non-financial incentives applicable to pharmaceutical, bulk drug (API), and medical device manufacturing units in Odisha, aimed at fostering investment, innovation, and global competitiveness.
- b. The Odisha Pharmaceuticals and Medical Devices Policy 2025 shall be read in conjunction with the Industrial Policy Resolution (IPR)-2022. All incentives and facilitation measures under this policy shall be governed by the provisions of IPR-2022, along with the additional sector-specific special incentives provided herein. Any aspect not explicitly covered under this policy shall be eligible for support under the applicable provisions of IPR-2022 and its subsequent amendments.
- c. In case of overlapping provisions across multiple policies, an eligible unit may exercise the option to avail benefits under only one applicable policy for a particular incentive component. The choice once made shall be binding and final.
- d. High-impact or strategic projects may be considered for a special package of incentives on a case-to-case basis, subject to evaluation by a High-Level Committee chaired by the Chief Secretary and final approval by the State Cabinet.
- e. The policy shall remain in force for a period of 5 years from its notification date or until replaced by a new policy, whichever is later. The Government may undertake mid-term reviews and incorporate amendments as required in response to evolving sectoral needs or policy priorities.
- f. Detailed operational guidelines, implementation procedures, application formats, and disbursement protocols shall be issued separately by the Department of Industries and shall form an integral part of this policy.
- g. The Government of Odisha reserves the right to review, modify, suspend, or withdraw any provision, incentive, or scheme outlined in this policy at any time, without prior notice, in the interest of public policy, administrative feasibility, or fiscal prudence. The decision of the Government shall be final and binding on all stakeholders. All units availing benefits under this policy shall be deemed to have agreed to comply with such changes, and no claim or compensation shall be entertained on account of such modifications or cancellations.
- h. Any ambiguity or dispute regarding this policy shall be resolved by the Department of Industries, Government of Odisha, whose decision shall be final and binding.

## **Annexure – 1: Definitions, Interpretations, and Abbreviations**

### **A.1. Definitions and Interpretations**

For the purpose of this Policy, the various terms shall have the meanings assigned to them hereunder:



1. **Pharmaceutical Industry** - Refers to units engaged in the manufacture, formulation, or research of drugs and therapeutic products, including Active Pharmaceutical Ingredients (APIs), bulk drugs, formulations, vaccines, biologicals, biosimilars, veterinary drugs, animal vaccines, Nutraceuticals, and cosmetics that are classified as drugs under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and their subsequent amendments.
2. **Medical Devices**- Refers to instruments, apparatus, appliances, implants, software, or other articles, including in-vitro diagnostic (IVD) devices, intended for use in humans or animals for diagnosis, prevention, monitoring, treatment, or alleviation of disease or injury. This includes medical wearable, digital health devices, and surgical consumables, as defined under the Medical Devices Rules, 2017 and its subsequent amendments.
3. **Pharmaceutical Unit** - A unit or undertaking located within Odisha and engaged in the manufacture, formulation, or processing of pharmaceutical products, APIs, drug intermediates, veterinary formulations, cosmetics, medical devices, or diagnostics.
4. **New Pharmaceutical Unit** - A pharmaceutical unit where fixed capital investment has commenced on or after the Effective Date of this policy and which commences commercial production within three years for MSMEs and five years for Large/Mega units from the date of first fixed capital investment. It includes Expansion / Modernization / Diversification / Up- gradation of an existing unit.
5. **Research s Development (R&D) Unit** : Refers to a facility engaged in scientific and technical research related to pharmaceuticals, medical devices, diagnostics, veterinary health, or cosmetics. Activities include drug discovery, formulation development, clinical research, prototype design, product testing, bioequivalence studies, or advanced therapy development (e.g., biologics, gene therapy). R&D units may be standalone or co-located with manufacturing units and must comply with GLP, GMP, or applicable National or international regulatory standards.

- 6. Testing & Calibration Laboratory :** Refers to a NABL-accredited or GLP/GMP-compliant facility that conducts quality testing, product validation, clinical analysis, or calibration of pharmaceutical or medical device components in compliance with applicable national or international norms.
- 7. Common Facility Centre (CFC) :** Refers to a shared infrastructure unit offering facilities such as effluent treatment, sterilization, warehousing, quality testing, or cold storage, serving multiple pharmaceutical or MedTech industries within an industrial cluster or park.
- 8. Eligible Units :** All New and E/M/D/U units eligible for all incentives under this policy.
- 9. Existing Pharmaceutical Unit -** A unit that commenced commercial production prior to the Effective Date of this policy.
- 10. Fixed Capital Investment (FCI) -** Investment in land, buildings, plant and machinery, clean room infrastructure, HVAC systems, quality labs, ETP/ZLD systems, and associated utilities integral to manufacturing, R&D, and regulatory compliance.
- 11. Micro, Small, Medium Enterprise (MSME) -** An enterprise as defined by the Government of Odisha from time to time.
- 12. Large Project -** A unit with an investment above 50 crore but below 500 crore or providing direct employment to more than 200 Odisha-domiciled persons.
- 13. Mega Project -** A unit with investment above 500 crore or direct employment to more than 500 Odisha-domiciled persons.
- 14. Anchor Industrial Unit / Lead Investment Initiator -** A new enterprise proposing a minimum investment of 2,000 crore or creating a minimum of 1,000 direct employment opportunities for Odisha-domiciled persons in pharmaceuticals, APIs, or medical devices sectors.
- 15. Pharmaceutical Park Developer -** Any private developer, industry association, or Special Purpose Vehicle (SPV) engaged in the development of industrial parks/clusters for pharmaceutical or medical device industries under Government approval.

16. **Operational Guidelines** - The detailed implementation framework issued by the Industries Department/IPICOL, covering application formats, timelines, eligibility criteria, approval processes, and disbursement mechanisms.
17. **Effective Date** - The date of official publication of this policy in the Odisha Gazette.
18. **SEZ Unit** - A pharmaceutical or medical device unit located within a Special Economic Zone (SEZ), notified under the SEZ Act, 2005.
19. **Skilled Personnel** - Individuals possessing domain-specific training, technical certifications, or qualifications relevant to the pharmaceutical or medical devices industry hold ITI certifications, diplomas, or equivalent qualifications recognized by Skill Odisha or national sector skill councils.
20. **High-Skilled Personnel** - Individuals with Minimum qualifications of degree- or postgraduates in pharmacy, life sciences, biomedical engineering, or related disciplines. This category includes R&D scientists, formulation specialists, regulatory professionals, process engineers, quality assurance managers, and medical device designers to perform complex functions in manufacturing, research, regulatory compliance, and innovation.
21. **Export-Oriented Unit (EOU)** - A unit exporting at least 50% of its annual production volume or value, verified via statutory export documentation.
22. **Start-up** - A unit recognized as a start-up by the Government of Odisha or Government of India, engaged in pharmaceutical, medical device, or life sciences innovation.
23. **Year (for the purpose of incentives)** - A period of 365 consecutive days from the date of commencement of commercial production.

## **A.2. Abbreviations**

1. API – Active Pharmaceutical Ingredient
2. AYUSH – Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homeopathy
3. CDSCO – Central Drugs Standard Control Organization
4. CETP – Common Effluent Treatment Plant
5. CRO – Contract Research Organization
6. CTMO – Clinical Trial Management Organization
7. DIC – District Industries Centre
8. DIPA – District Investor Promotion Agency
9. DLSWCA – District Level Single Window Clearance Authority
10. DPIIT – Department for Promotion of Industry and Internal Trade
11. E/M/D/U – Expansion / Modernization / Diversification / Upgradation
12. EPF – Employees' Provident Fund
13. ESI – Employees' State Insurance
14. ETP – Effluent Treatment Plant
15. FCI – Fixed Capital Investment
16. GLP – Good Laboratory Practice
17. GMP – Good Manufacturing Practice
18. GO SWIFT – Single Window for Investor Facilitation and Tracking
19. GSDP – Gross State Domestic Product
20. HLCA – High-Level Clearance Authority
21. ICMR – Indian Council of Medical Research
22. IPICOL – Industrial Promotion and Investment Corporation of Odisha Limited
23. IPR – Industrial Policy Resolution
24. IVD – In-Vitro Diagnostics
25. KSM – Key Starting Material
26. MSME – Micro, Small and Medium Enterprises
27. NABL – National Accreditation Board for Testing and Calibration Laboratories
28. NSDC – National Skill Development Corporation
29. ODLMS – Online Drugs License Management System (Odisha)
30. ONDLS – Online National Drugs Licensing System
31. OPDC – Odisha Pharmaceutical Development Cell

- 
32. QA/QC – Quality Assurance / Quality Control
  33. R&D – Research and Development
  34. SEZ – Special Economic Zone
  35. SGST – State Goods and Services Tax
  36. SLSWCA – State-Level Single Window Clearance Authority
  37. SPV – Special Purpose Vehicle
  38. US-FDA – United States Food and Drug Administration
  39. WHO-GMP – World Health Organization – Good Manufacturing Practices
  40. ZLD – Zero Liquid Discharge
- 

## **Annexure 2: Recognized Industrial Activities under this Policy**

For the purpose of eligibility under this policy, the following categories of undertakings shall be recognized as industrial units:

### **Eligible Activities**

Only Manufacturing, Research & Development Units of Pharmaceuticals, Active Pharmaceutical Ingredients (API), Bulk Drugs, Biotechnology, Medical Devices, Veterinary Medicines, Cosmetics, and Nutraceuticals (as classified under the Drugs and Cosmetics Act & Rules) shall be eligible under this policy.

### **Regulatory Conformance**

The activities must conform to the definitions and standards under:

- i The Drugs and Cosmetics Act, 1S40, and Rules, 1S45, along with any subsequent amendments, for Drugs, Cosmetics, Nutraceuticals, and Veterinary preparations.
- ii The Medical Devices Rules, 2017, and its subsequent amendments, for medical devices and diagnostics.

#### **A. Manufacturing Units:**

- i Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs)
- ii Bulk drugs and drug intermediates
- iii Finished formulations (oral, injectable, topical, transdermal, etc.)
- iv Vaccines, Biosimilars, and Biopharmaceuticals
- v Biological including sera, Immunoglobulins, and Immunomodulators
- vi Medical devices, in-vitro diagnostics (IVDs), surgical instruments, implants, and wearable
- vii Cosmetics and Nutraceuticals regulated under the Drugs and Cosmetics Act and manufactured in compliance with Schedule M or WHO-GMP
- viii Veterinary Pharmaceuticals, Biologicals, and animal health products under applicable drug provisions
- ix Pharmaceutical Common Effluent Treatment Plants (ETPs), Zero Liquid Discharge (ZLD) systems
- x Private industrial parks, SEZ-based units, MedTech clusters, and biotech zones developed by public or private bodies

## **B. Research, Testing and Innovation Units**

- i Research centres focused on drug discovery, formulation, and process optimization
- ii Clinical trial management organizations (CTMOs), Contract Research Organizations (CROs), and pre-clinical labs
- iii Medical device design, validation, and prototyping labs
- iv GLP/GMP-certified testing, calibration, and analytical facilities
- v AI-enabled health-tech and computational platforms for drug and device development

## Industries Department, Govt. of Odisha

Name & Designation	Address	Email ID	Office. Tel. No
Principal Secretary, Industries Department	Industries Department 6th Floor, Kharavel Bhawan, Bhubaneswar - 751 001	indsec.or@nic.in	0674-2536640 0674-2390253
Special Secretary, Industries Department	Industries Department 6th Floor, Kharavel Bhawan, Bhubaneswar - 751 001		0674-2392344
Special Secretary, Industries Department	Industries Department 6th Floor, Kharavel Bhawan, Bhubaneswar - 751 001		0674-2535670
Additional Director, Industries Department	Industries Department 6th Floor, Kharavel Bhawan, Bhubaneswar - 751 001		0674-2395089

## MSME Department, Govt. of Odisha

Name & Designation	Address	Email ID	Office. Tel. No
Principal Secretary, MSME Department	Micro, Small & Medium Enterprises Department, 6th Floor, Kharavel Bhawan, Bhubaneswar - 751 001	secy.msme.od @nic.in	0674-2391384
Director of Industries	Directorate of Industries Killa Maida, Buxi Bazar, Cuttack - 753 001	diorissa@nic.in	0671-2301892

## Health & Family Welfare Department, Govt. of Odisha

Name & Designation	Address	Email ID	Office. Tel. No
Commissioner -cum-Secretary	Health & FW Department Lok Seva Bhawan, Lok Seva Marg, Unit-5, Bhubaneswar, Odisha. 751001	orhealth@nic.in	0674-2536632
MD. NHM(O)		issiondirector @nic.in	0674-2635067
Director Health Service		dhsodisha@ gmail.com	0674-2391536
Director F.W		dfwodisha@ gmail.com	0674-2391625
D.M.E.T			0674-2393847
MD OSMCL		mdosmcl.od @nic.in	

## Industrial Promotion & Investment Corporation of Odisha Limited (IPICOL)

Name & Designation	Address	Email ID	Office. Tel. No
Chairman, IPICOL	IPICOL House, Janpath, Saheed Nagar, Bhubaneswar - 751 022	cmd@investodisha.org	0674-2543461
Managing Director, IPICOL	IPICOL House, Janpath, Saheed Nagar, Bhubaneswar - 751 022	md@investodisha.org	0674-2543461
Executive Director, IPICOL	IPICOL House, Janpath, Saheed Nagar, Bhubaneswar - 751 022	ed@investodisha.org	
Chief General Manager (SLNA) IPICOL	IPICOL House, Janpath, Saheed Nagar, Bhubaneswar - 751 022	rajibdhal@ investodisha.org	
General Manager (IP), IPICOL	IPICOL House, Janpath, Saheed Nagar, Bhubaneswar - 751 022	debasish.das@ investodisha.org	

## IDCO

Name & Designation	Address	Email ID	Office. Tel. No
Chairman, IDCO	IDCO Tower, Janpath, Bhubaneswar - 751 022	cmd@idco.in	0674-2540820 0674-2542820
Managing Director, IDCO	IDCO Tower, Janpath, Bhubaneswar - 751 022	md@idco.in	0674-2540820 0674-2542820
CGM Land	IDCO Tower, Janpath, Bhubaneswar - 751 022	cgmland@idco.in	
CGM MSME	IDCO Tower, Janpath, Bhubaneswar - 751 022	cgmmsme@idco.in	

## Directorate of Drug Control, Govt. of Odisha

Name & Designation	Address	Email ID	Office. Tel. No
Drugs Controller	DIRECTORATE OF DRUGS CONTROL: ODISHA, At: Gajapati Nagar, Bhubaneswar-751017	drugscontrolorissa@gmail.com	9437013646
Joint Drugs Controller (Intelligence & Enforcement)		drugscontrolorissa@gmail.com	9437013646
Joint Drugs Controller (Quality Control)		drugscontrolorissa@gmail.com	9437136217
Deputy Drugs Controller (Intelligence, Directorate of Drugs Control)		ddcintodisha@gmail.com	7008979252
Deputy Drugs Controller (Administration, Directorate of Drugs Control)		ddcadmndca@gmail.com	9437232661
Coordinator,OPDC		opdc.govt@gmail.com	8895478543
Deputy Drugs Controller (Southern Zone, Berhampur)	Office of Deputy Drugs Controller, (Southern Zone), Berhampur, Ganjam, Odisha	ddcsz.bam@gmail.com	9437262972
Deputy Drugs Controller(North Zone, Balasore)	Office of Deputy Drugs Controller, (North Zone), Balasore, Odisha	ddcnorthzone@gmail.com	9439708300
Deputy Drugs Controller (Western Zone, Sambalpur)	Office of Deputy Drugs Controller, (Western Zone), Sambalpur, Odisha	ddcwzsambalpur@gmail.com	8249090732

## Odisha Pharmaceutical Development Cell (OPDC)



### GOVERNMENT OF ODISHA HEALTH & FAMILY WELFARE DEPARTMENT

\*\*\*\*\*

#### NOTIFICATION

File No. HFW-DCMA-MISC-0108-2024- ୨୩୭୮୯ /H&F.W. Dated 16-08-2025

Pursuant to the kind observation of the Hon'ble Chief Minister, Odisha communicated vide UOI No. 193 dtd. 12.12.2024, the committee of the Odisha Pharmaceutical Development Cell (OPDC) is hereby constituted with the following Members.

1	The Chief Secretary, Odisha	Chairman
2	The Principal Secretary to Government, Industries Department	Member
3	The Principal Secretary to Government, Micro, Small and Medium Enterprises Department	Member
4	The Commissioner-cum-Secretary to Government, Health and Family Welfare Department	Member
5	The Drugs Controller, Odisha, Bhubaneswar	Nodal Officer and Convener
6	Sri Chandan Kumar Giri Drugs Inspector, Bhubaneswar-II	Coordinator

This will take effect from the date of issue of the Notification.

**ORDER:** Ordered that the Notification be published in the next issue of the Odisha Gazette

By order of the Governor

## District Industries Centre

Name of District	Address	Email ID
<b>Angul</b>	PSI Unit Chhak, Hemsurpada, Angul - 759 122	dicangul@nic.in
<b>Balasore</b>	Angargadia, Near ITI, Balasore, Balasore - 756 001	dicbal@nic.in
<b>Baragarh</b>	Rly. Station Road, Near Sharma Motors, Baragarh - 768 028	dicbargarh@nic.in
<b>Bhadrak</b>	Buddha Vihar, Bhadrak - 7561 00	dicbhadrak@nic.in
<b>Khordha</b>	Industrial Estate, Rasulgarh, Bhubaneswar - 751 010	dicbbs@nic.in
<b>Bolangir</b>	Near Civil Court, Patanagarh road, Bolangir - 767 001	dicblg@nic.in
<b>Boudh</b>	Boudh bazar, Boudh - 762 014	dicboudh@nic.in
<b>Cuttack</b>	Industrial Estate, Khapuria, Madhupatna, Cuttack - 753 010	dicctc@nic.in
<b>Deogarh</b>	Babusahi, Behind Head Post office, Deogarh - 768 108	dicdeogarh@nic.in
<b>Dhenkanal</b>	Mahinsapata, Dhenkanal - 759 013	ricdkl@nic.in
<b>Gajapati</b>	Katikiasahi, Paralakhemundi, Gajapati - 761 200	dicgajapati@nic.in
<b>Ganjam</b>	Industrial Estate, Berhampur - 760 008	dicgan@nic.in
<b>Jajpur</b>	RIC, Kalinganagar	rickngr@nic.in
<b>Jagatsinghpur</b>	District Industries Centre, Jogadhari, Jagatsinghpur - 754 103	dicjspur@nic.in
<b>Jharasuguda</b>	Industrial Estate, Jharasuguda - 768 203	dicjharsuguda@nic.in
<b>Kalahandi</b>	Near Manikeswari Chhak, Bhawanipatna - 766 001	dickal@nic.in
<b>Kendrapara</b>	Gualsingh, Pandiri, Near Law College, Kendrapara - 754 211	dickendrapara@nic.in
<b>Keonjhar</b>	Near Orissa School of Mining, Keonjhar - 758 001	dickjr@nic.in
<b>Koraput</b>	Christianpeta, Near M.I. Colony, Jeypore -764 005	dickor@nic.in
<b>Malkangiri</b>	Main Road, Near SBI, Malkangiri - 764 045	dicmalkangiri@nic.in
<b>Mayurbhanj</b>	Baripada, Mayurbhanj - 757 001	orimay@nic.in
<b>Nawarangpur</b>	Rani Jhansi Marg, P, O. Nabarangpur, Nawarangapur- 764 059	dicnabarangpur@nic.in
<b>Nayagarh</b>	Khandapada road, Nayagarh - 752 069	dicnayagarh@nic.in
<b>Nuapada</b>	Near NAC Office, Khariar Road, Nuapada - 766 104	dicnuapada@nic.in
<b>Phulbani</b>	Hospital Chhak, Phulbani - 762 001	dicphb@nic.in
<b>Puri</b>	Chakratirtha Road, Puri - 752 002	dicpur@nic.in
<b>Rayagada</b>	Cooperative Colony, Convent School road, Rayagada - 765 001	ricrgd@nic.in
<b>Rourkela</b>	Near Jail, Industrial Estate, Rourkela - 769 004	ricrou@nic.in
<b>Sambalpur</b>	Bhutapada chhak, Jail Road, Sambalpur - 768 001	ricsam@nic.in
<b>Sonepur</b>	Khadalpada, Medical Road, Sonepur - 767 016	dicsubarnapur@nic.in
<b>Sundargarh</b>	Near Tahasil Office, Sundargarh - 770 001	dicsng@nic.in


## District Investment Promotion Agencies (DIPA)

District Investment Promotion Agency (DIPA) has been formed to streamline the investment facilitation mechanism by setting up offices at district level.

The following district has DIPA offices.

District	Email ID
Sl. No.	District Name
<b>HEAD OFFICE</b>	dipaops@investodisha.org
AUGUL	dipa.angul@investodisha.org
BOUDH	dipa.boudh@investodisha.org
BALANGIR	dipa.bolangir@investodisha.org
BARGARH	dipa.bargarh@investodisha.org
BALASORE	dipa.balasore@investodisha.org
BHADRAK	dipa.bhadrak@investodisha.org
CUTTACK	dipa.cuttack@investodisha.org
DEOGARH	dipa.deogarh@investodisha.org
DHENKANAL	dipa.dhenkanal@investodisha.org
GANJAM	dipa.ganjam@investodisha.org
GAJAPATI	dipa.gajapati@investodisha.org
JHARSUGUDA	dipa.jharsuguda@investodisha.org
JAJPUR	dipa.jajpur@investodisha.org
JAGATSINGHPUR	dipa.jagatsinghpur@investodisha.org
KHORDHA	dipa.khurda@investodisha.org
KEONJHAR	dipa.keonjhar@investodisha.org
KALAHANDI	dipa.kalahandi@investodisha.org
KANDHAMAL	dipa.kandhamal@investodisha.org
KORAPUT	dipa.koraput@investodisha.org
KENDRAPADA	dipa.kendrapara@investodisha.org
MALKANGIRI	dipa.malkangiri@investodisha.org
MAYURBHANJ	dipa.mayurbhanj@investodisha.org
NABARANGPUR	dipa.nabarangpur@investodisha.org
NUAPADA	dipa.nuapada@investodisha.org
NAYAGARH	dipa.nayagarh@investodisha.org
PURI	dipa.puri@investodisha.org
RAYAGADA	dipa.rayagada@investodisha.org
SAMBALPUR	dipa.sambalpur@investodisha.org
SUBARNAPUR	dipa.subarnapur@investodisha.org
SUNDARGARH	dipa.sundergarh@investodisha.org

## First-of-its-kind single window portal to ensure investor delight





Industrial Promotion & Investment Corporation of Odisha Limited (IPICOL)

IPICOL House, Janpath, Bhubaneswar – 751022, Odisha

✉ info@investodisha.org ☎ 1800 345 7111

For further information please visit <http://www.investodisha.gov.in/>

Follow us on [Twitter](#) @investInOdisha [Facebook](#) /InvestOdisha [YouTube](#) [LinkedIn](#) Invest Odisha